Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.
2026-08-09 13:15
•James Brumley •The Motley Fool
••• • Axe Cap view
What Johnson & Johnson’s Dividend Legacy Means for SA Investors
JNJ’s 64 years of dividend growth show steady income and growth, a mix rarely seen on the JSE.
Johnson & Johnson’s record as a Dividend King—a company raising its dividend every year for 64 years—speaks to rare reliability. For US investors, a $10,000 stake now yields around $210 annually, which isn’t huge but offers solid income with growth potential. J&J’s recent moves into oncology push it beyond just a slow-and-steady pharma player into growth territory. While buy-and-hold dividend stocks are less common on the JSE, the steady income mindset is relevant. South African defensive plays like Sanlam and MTN offer dividends, but few combine consistent growth with the innovation J&J shows. For local investors chasing emerging market risk and rand volatility, following a US Dividend King currency-hedged via USD/ZAR could diversify income streams. That said, J&J’s modest 5.3% dividend growth could disappoint those looking for quick gains. Currency swings in USD/ZAR remain a wildcard too, potentially eroding returns. this is just our opinion and not financial advice
For steady income with modest growth, consider adding dividend-focused US equities like JNJ through rand-hedged ETFs or offshore funds, while trimming some local high-volatility exposure. Keep USD/ZAR on your radar as currency shifts influence offshore returns.
- JNJ
- USD/ZAR
- rand volatility impacting offshore returns
- modest dividend growth pace may disappoint income seekers
6/10
Johnson & Johnson maintains its status as a Dividend King with 64 consecutive years of dividend increases. A $10,000 investment would generate approximately $210 annually at the current 2.1% dividend yield. While dividend growth has been modest at 5.3% annually over the past decade, J&J is increasingly positioned as a growth stock following strategic acquisitions in oncology, with the stock gaining nearly 80% since end of 2024.
Our take is based on reporting first published by The Motley Fool.